Miragen Therapeutics (NASDAQ:MGEN)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a note issued to investors on Tuesday.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research note on Thursday. B. Riley began coverage on shares of Miragen Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $15.50 target price for the company. Wedbush reiterated a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. Oppenheimer began coverage on shares of Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 price target on the stock. Finally, Cann began coverage on shares of Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Miragen Therapeutics presently has an average rating of “Buy” and an average target price of $16.46.
Miragen Therapeutics (NASDAQ:MGEN) traded up $0.12 during mid-day trading on Tuesday, reaching $8.04. 80,657 shares of the company were exchanged, compared to its average volume of 275,920. Miragen Therapeutics has a 12 month low of $6.02 and a 12 month high of $18.00. The company has a market capitalization of $176.69, a P/E ratio of 53.60 and a beta of 1.91. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.
In other news, Director Thomas E. Hughes sold 12,000 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total transaction of $96,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 44.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Seaward Management Limited Partnership purchased a new stake in shares of Miragen Therapeutics during the third quarter valued at approximately $117,000. Russell Investments Group Ltd. purchased a new stake in Miragen Therapeutics in the third quarter worth approximately $147,000. BSW Wealth Partners purchased a new stake in Miragen Therapeutics in the third quarter worth approximately $203,000. Finally, SG Americas Securities LLC purchased a new stake in Miragen Therapeutics in the third quarter worth approximately $250,000. Hedge funds and other institutional investors own 22.64% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3147890/miragen-therapeutics-mgen-buy-rating-reaffirmed-at-chardan-capital.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.